Mitochondria in steatohepatitis

Seminars in Liver Disease

Volumn 21, Issue 1, 2001, Pages 57-69

  Pessayre, D ^a   Berson, A ^a   Fromenty, B ^a   Mansouri, A ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Cytokine; Fas; Lipids; Mitochondria; Peroxidation; Reactive oxygen species; Steatohepatitis; Steatosis

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CYTOKINE; FAS LIGAND; FATTY ACID; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; LIPID; METFORMIN; PERHEXILINE; REACTIVE OXYGEN METABOLITE; SIBUTRAMINE; TAMOXIFEN; UNCOUPLING PROTEIN 2;

AGING; ALCOHOL ABUSE; CELL DEATH; DIET RESTRICTION; DRUG INDUCED DISEASE; ENERGY METABOLISM; EXERCISE; FATTY LIVER; GLUCOSE METABOLISM; HEPATITIS; HEREDITY; HUMAN; INTESTINE BYPASS; LIPID OXIDATION; LIPID PEROXIDATION; LIVER CIRRHOSIS; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; WILSON DISEASE;

EID: 0035082457     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-12929     Document Type: Review

References (153)

1. Obesity as a medical problem
2. Relative antioxidant deficiency in obese children: A weighty contributor to morbidity?
3. Profile of an urban hospital-based practice
4. Nonalcoholic steatohepatitis (NASH): Potential causes and pathogenic mechanisms
5. Fatty liver - An additional and treatable feature of the insulin resistance syndrome
6. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM
7. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects
8. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis
9. Association of nonalcoholic fatty liver disease with insulin resistance
10. Severe insulin resistance syndromes and NASH
11. The liver in obesity
12. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus
13. Nonalcoholic steatohepatitis: A study of 49 patients
14. Nonalcoholic steatohepatitis
15. Non-alcoholic steatohepatitis: Another disease of affluence
16. Nonalcoholic steatohepatitis
17. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity
18. Liver failure and mitochondrial disease
19. Drug-induced steatosis and steatohepatitis
20. Mitochondria and apoptosis
21. Mitochondrial disease in man and mouse
22. Oxidative phosphorylation at the fin de siècle
23. Regulation of hepatic fatty acid oxidation and ketone body production
24. Oxidative damage and mitochondrial decay in aging
25. Repair of alkylation and oxidative damage in mitochondrial DNA
26. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and adjacent residues
27. Action of mitochondrial DNA polymerase γ at sites of base loss or oxidative damage
28. Singlet oxygen mediates the UVA-induced generation of the photoaging-associated mitochondrial common deletion
29. Liver mitochondrial respiratory functions decline with age
30. Structure and ultrastructure of the liver in aged persons
31. A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues
32. Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication
33. Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species
34. Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals
35. Oxidative stress, caloric restriction, and aging
36. Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster
37. Simultaneous overexpression of copper and zinc-containing superoxide dismutase and catalase retards age-related oxidative damage and increases metabolic potential in Drosophila melanogaster
38. Mitochondrial disease in mouse results in increased oxidative stress
39. Up-regulation of nuclear and mitochondrial genes in the skeletal muscle of mice lacking the heart/muscle isoform of the adenine nucleotide translocator
40. Role of adenine nucleotide translocator 1 in mtDNA maintenance
41. Liver failure associated with mitochondrial DNA depletion
42. Fatal neonatal liver failure and mitochondrial cytopathy (oxidative phosphorylation deficiency): A light and electron microscopic study of the liver
43. Adaptations of mitochondrial gene expression to changing cellular energy demands
44. Mitochondrial control of cell death
45. Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous substances and foreign toxins)
46. Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: Different forms of drug-induced hepatic apoptosis
47. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis
48. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice
49. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation and apoptosis in rat hepatocytes
50. Activation of NF-κB in vivo is regulated by multiple phosphorylations
51. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived oxygen species and the activation of NF-κB
52. Role of reactive oxygen species and p53 in chromium(VI)-induced apoptosis
53. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
54. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
55. Metabolic and nutritional considerations in nonalcoholic fatty liver
56. Non-esterified fatty acids in blood of obese and lean subjects
57. Plasma free fatty acid turnover in obesity
58. Markers of capacity to utilize fatty acids in human skeletal muscle: Relation to insulin resistance and obesity and effects of weight loss
59. Cellular mechanisms of insulin resistance
60. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
61. Liver fibrosis in overweight patients
62. The natural history of non-alcoholic fatty liver: A follow up study
63. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice
64. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis
65. Evidence for mitochondrial DNA damage by lipid peroxidation
66. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme catalytic site
67. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase
68. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor
69. Mitochondrial abnormalities in non-alcoholic steatohepatitis
70. Activity of the mitochondrial respiratory chain enzymes is decreased in the liver of patients with nonalcoholic steatohepatitis
71. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study
72. 2 generation in liver mitochondria
73. Lipids upregulate uncoupling protein 2 expression in rat hepatocytes
74. Mitochondrial adaptations to obesity-related oxidant stress
75. Abnormal antioxidant defence in some tissues of congenitally obese mice
76. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse
77. Glutathione depletion by hyperphagia-induced obesity
78. Comparison of serum concentrations of α-tocopherol and β-carotene in a cross-sectional sample of obese and nonobese children (NHANES III)
79. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
80. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
81. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation
82. Effects of obesity on the cytochrome P450 enzyme system
83. A genetic polymorphism in regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake
84. Nonalcoholic steatohepatitis: An expanded clinical entity
85. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 Finnish men
86. Serum ferritin as a component of the insulin resistance syndrome
87. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
88. Insulin resistance-associated hepatic iron overload
89. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
90. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol abusers
91. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice
92. Hepatic mitochondrial DNA deletion in alcoholics: Association with microvesicular steatosis
93. Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients
94. Hepatocyte proliferation and serum hepatocyte growth factor levels in patients with alcoholic hepatitis
95. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation
96. Study of mitochondrial DNA deletion in alcoholics
97. Increased oxidative damage to mitochondrial DNA following chronic ethanol consumption
98. Oxidation of mitochondrial proteins and DNA following administration of ethanol
99. Implication of free radical mechanisms in ethanol-induced cellular injury
100. Biochemical and morphological alterations of baboon hepatic mitochondria after chronic ethanol consumption
101. Effects of chronic ethanol consumption on the synthesis of polypeptides encoded by the hepatic mitochondrial genome
102. Molecular alterations in the respiratory chain of rat liver after chronic ethanol consumption
103. Increased production of reactive oxygen species by rat liver mitochondria after chronic ethanol treatment
104. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease
105. Oxidative phosphorylation defects in liver of patients with Wilson's disease
106. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II
107. Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice
108. Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondria. Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels and cell survival
109. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions
110. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
111. Chemistry and biochemistry of 4hydroxynonenal, malondialdehyde and related aldehydes
112. High molecular weight components are main constituents of Mallory bodies isolated with a fluorescence activated cell sorter
113. Mallory body formation by ethanol feeding in drug-primed mice
114. Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: Association of lipid peroxidation with liver fibrogenesis
115. Stimulation of collagen α-1 (I) gene expression is associated with lipid peroxidation in hepatocellular injury: A link to tissue fibrosis?
116. Chemotactic activity of hydroxyalkenals on rats neutrophils
117. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: A link between oxidative injury and fibrosclerosis
118. Nuclear migration of NF-κB correlates with TNF-α mRNA accumulation
119. Variation in immunocytochemical expression of transforming growth factor (TGF)-beta in hepatocytes in culture and liver slices
120. Cytokine expression in hepatocytes: Role of oxidative stress
121. Zonated expression of cytokines in rat liver: Effects of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole
122. Role of cytokines in ethanol-induced cytotoxicity in vitro in HepG2 cells
123. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function
124. Processing/activation of CPP32-like proteases is involved in transforming growth factor β1-induced apoptosis in rat hepatocytes
125. Identification of a transforming growth factor-β1/bone morphogenic protein 4 (TGF-β1/BMP4) response element within tissue transglutaminase gene promoter
126. Association of a transglutaminase-related antigen with intermediate filaments
127. Regulation of extracellular matrix synthesis by transforming growth factor-β1 in human fat storing cells
128. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines
129. Inactivation of Kupffer cells prevents early alcohol-induced liver injury
130. Antibodies to tumor necrosis factor-α attenuate hepatic necrosis and inflammation due to chronic exposure to ethanol in rats
131. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice
132. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis
133. Human Fas ligand: Gene structure, chromosomal location and species specificity
134. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells
135. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
136. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis
137. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
138. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia
139. Transport function and regulation of mitochondrial uncoupling proteins 2 and 3
140. Involvement of the dicarboxylate carrier in the protonophoric action of long-chain fatty acids in mitochondria
141. Genetics of body weight regulation
142. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus
143. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease
144. Nonalcoholic steatohepatitis
145. Hepatic effects of dietary weight loss in morbidly obese subjects
146. Long-term consequences after jejunoileal bypass for morbid obesity
147. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty
148. Effect of fasting on metabolite-mediated hepatotoxicity in the rat
149. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor
150. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
151. Fatty liver - An additional and treatable feature of the insulin resistance syndrome
152. Medicinal strategies in the treatment of obesity
153. Metformin reverses fatty liver disease in obese, leptin-deficient mice